Physician

Priyantha S. Ranaweera, M.D.

According to 2025 Medicare claims, Priyantha Ranaweera, M.D. (NPI: 1497952998) practices cardiology in the Manhattan, KS market, with the plurality of this provider's patient population coming from Riley, KS. This provider's primary affiliated billing organization is MANHATTAN MEDICAL GROUP, LLC (NPI: 1609138387; TIN: 45-5420179) and primary practice location at 66503-3049. Ranaweera is affiliated with the Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Ranaweera's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,259 traditional Medicare patients, billed 13,416 HCPCS/CPT codes, and received $1,027,352 in Medicare payments. The top billing code was 78452 (Nuclear medicine studies of heart muscle at rest and with stress and spect). Part D data shows 7,128 prescription claims across 830 beneficiaries totaling $1,408,704 in drug costs, led by Eliquis (Apixaban). 2023 DME data shows 515 claims. Open Payments data shows 94 records totaling $7,291. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $768,508 and ending at $1,027,352. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $319,267 to $1,408,704. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $47,051 to $12,821.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,095	7,473	$768,508
2016	1,088	9,569	$2,275,442
2017	1,206	10,996	$2,405,729
2018	1,186	10,930	$1,368,320
2019	1,306	12,969	$1,745,300
2020	1,123	12,706	$1,232,083
2021	1,164	13,803	$1,149,436
2022	1,308	13,283	$928,252
2023	1,379	16,057	$1,168,889
2024	1,259	13,416	$1,027,352

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	393	4,554	$319,267
2016	399	5,181	$377,589
2017	467	5,879	$427,667
2018	488	5,631	$503,901
2019	559	5,682	$542,497
2020	536	5,533	$624,324
2021	562	5,192	$723,931
2022	686	5,490	$987,589
2023	756	6,489	$1,383,953
2024	830	7,128	$1,408,704

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	24	$46,885
2016	N/R	25	$52,253
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	191	280	$73,369
2020	N/R	13	$802
2021	N/R	N/R	N/R
2022	N/R	21	$48,512
2023	512	515	$2,185,118
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78452	Nuclear medicine studies of heart muscle at rest and with stress and spect	307	308	$266
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	799	841	$112
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	316	450	$85
93015	Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician	299	306	$45
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	442	499	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	398	18,752	$362,071
Entresto	Sacubitril/Valsartan	352	14,493	$306,894
Jardiance	Empagliflozin	193	8,522	$154,099
Farxiga	Dapagliflozin Propanediol	174	8,388	$153,293
Xarelto	Rivaroxaban	161	7,670	$142,187

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	94	$7,291	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Priyantha S. Ranaweera, M.D.?

Tedicare shows public-source Medicare data for Priyantha S. Ranaweera, M.D. (NPI 1497952998), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Priyantha S. Ranaweera, M.D. have ACO affiliation data?

Priyantha S. Ranaweera, M.D. is shown with ACO affiliation data for Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Priyantha S. Ranaweera, M.D.?

Priyantha S. Ranaweera, M.D. is linked to MANHATTAN MEDICAL GROUP, LLC (billing NPI 1609138387) in the available physician profile data.

Does Priyantha S. Ranaweera, M.D. have Open Payments data?

Priyantha S. Ranaweera, M.D. has 94 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.